Q-omics provides the consensus-scored DAD1 profile across patient tissues and cancer cell-line models. DAD1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DAD1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, DAD1 protein abundance shows 26,806 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, BLCA, and GBM as cancer lineages where DAD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DAD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DAD1 survival associations across molecular data types. DAD1 RNA expression shows survival associations in the most cancer types (28), followed by mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DAD1 RNA expression–survival associations across cancer types. High DAD1 expression shows unfavorable associations in HNSC, BLCA, UVM, ACC, LIHC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for DAD1 RNA expression.
This table summarizes DAD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DAD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DAD1 shows lower tumor expression in THCA and KICH and higher tumor expression in BLCA, HNSC, LIHC and BRCA. The BLCA box plot shows higher DAD1 RNA expression in tumor versus normal tissue (log2 FC = +0.545, t-test p < 0.001).
This table shows molecular features associated with DAD1 in patient tissues and cancer cell lines. In patient samples, DAD1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DAD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
